|
| 34515877 | Phase I study of cediranib, an oral VEGFR inhibitor, in combination with selumetinib, an oral MEK inhibitor, in patients with advanced solid malignancies. | Invest New Drugs | 2022 |
| 34316715 | Characterization of a <i>RAD51C</i>-silenced high-grade serous ovarian cancer model during development of PARP inhibitor resistance. | NAR Cancer | 2021 |
| 33852121 | Randomized Phase II Trial of Capecitabine and Lapatinib with or without IMC-A12 (Cituxumumab) in Patients with HER2-Positive Advanced Breast Cancer Previously Treated with Trastuzumab and Chemotherapy: NCCTG N0733 (Alliance). | Breast Cancer Res Treat | 2021 |
| 33850213 | Statistical analysis of comparative tumor growth repeated measures experiments in the ovarian cancer patient derived xenograft (PDX) setting. | Sci Rep | 2021 |
| 34642026 | Results of TRIO-14, a phase II, multicenter, randomized, placebo-controlled trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-ganitumab in newly diagnosed epithelial ovarian cancer. | Gynecol Oncol | 2021 |
| 34611148 | Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer. | NPJ Breast Cancer | 2021 |
| 32260077 | Disruption of Glycogen Utilization Markedly Improves the Efficacy of Carboplatin against Preclinical Models of Clear Cell Ovarian Carcinoma. | Cancers (Basel) | 2020 |
| 31787526 | Phase 1 trial of Vismodegib and Erlotinib combination in metastatic pancreatic cancer. | Pancreatology | 2020 |
| 32104500 | Anti-CDCP1 immuno-conjugates for detection and inhibition of ovarian cancer. | Theranostics | 2020 |
| 32816943 | Phase I and Pharmacokinetic Study of Romidepsin in Patients with Cancer and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study. | Clin Cancer Res | 2020 |
| 32554541 | Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE). | Clin Cancer Res | 2020 |
| 32473302 | Prognostic gene expression signature for high-grade serous ovarian cancer. | Ann Oncol | 2020 |
| 31004097 | Gene expression differences between matched pairs of ovarian cancer patient tumors and patient-derived xenografts. | Sci Rep | 2019 |
| 29138343 | A Phase I Clinical Trial of the Poly(ADP-ribose) Polymerase Inhibitor Veliparib and Weekly Topotecan in Patients with Solid Tumors. | Clin Cancer Res | 2018 |
| 29788332 | Constitutive Interferon Pathway Activation in Tumors as an Efficacy Determinant Following Oncolytic Virotherapy. | J Natl Cancer Inst | 2018 |
| 28073843 | Active Estrogen Receptor-alpha Signaling in Ovarian Cancer Models and Clinical Specimens. | Clin Cancer Res | 2017 |
| 28461031 | Phase 2 trial of everolimus and letrozole in relapsed estrogen receptor-positive high-grade ovarian cancers. | Gynecol Oncol | 2017 |
| 28423358 | Characterization of fusion genes in common and rare epithelial ovarian cancer histologic subtypes. | Oncotarget | 2017 |
| 28658648 | Prevention of Human Lymphoproliferative Tumor Formation in Ovarian Cancer Patient-Derived Xenografts. | Neoplasia | 2017 |
| 26946093 | High expression of orphan nuclear receptor NR4A1 in a subset of ovarian tumors with worse outcome. | Gynecol Oncol | 2016 |
| 26324738 | Clinical and Translational Results of a Phase II, Randomized Trial of an Anti-IGF-1R (Cixutumumab) in Women with Breast Cancer That Progressed on Endocrine Therapy. | Clin Cancer Res | 2016 |
| 26581242 | A First-in-Human Phase I Study of the Oral p38 MAPK Inhibitor, Ralimetinib (LY2228820 Dimesylate), in Patients with Advanced Cancer. | Clin Cancer Res | 2016 |
| 27765027 | Ridaforolimus (MK-8669) synergizes with Dalotuzumab (MK-0646) in hormone-sensitive breast cancer. | BMC Cancer | 2016 |
| 27614696 | In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma. | Gynecol Oncol | 2016 |
| 25398436 | Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer. | Cancer Res | 2015 |
| 26408297 | Molecular and clinical implementations of ovarian cancer mouse avatar models. | Chin Clin Oncol | 2015 |
| 26217584 | Understanding the Key to Targeting the IGF Axis in Cancer: A Biomarker Assessment. | Front Oncol | 2015 |
| 25962155 | Conventional chemotherapy and oncogenic pathway targeting in ovarian carcinosarcoma using a patient-derived tumorgraft. | PLoS One | 2015 |
| 25712686 | The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer. | Clin Cancer Res | 2015 |
| 25695953 | A novel neutralizing antibody targeting pregnancy-associated plasma protein-a inhibits ovarian cancer growth and ascites accumulation in patient mouse tumorgrafts. | Mol Cancer Ther | 2015 |
| 25783201 | Prioritizing therapeutic targets using patient-derived xenograft models. | Biochim Biophys Acta | 2015 |
| 25779953 | TBCRC 019: A Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel with or without the Anti-Death Receptor 5 Monoclonal Antibody Tigatuzumab in Patients with Triple-Negative Breast Cancer. | Clin Cancer Res | 2015 |
| 23340390 | Intrathecal metastases causing conus medullaris syndrome. | QJM | 2014 |
| 25290091 | A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours. | Br J Cancer | 2014 |
| 25318936 | Pharmacokinetics of endoxifen and tamoxifen in female mice: implications for comparative in vivo activity studies. | Cancer Chemother Pharmacol | 2014 |
| 25016924 | A phase II study of ramucirumab (IMC-1121B) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma. | Gynecol Oncol | 2014 |
| 25123819 | Can we unlock the potential of IGF-1R inhibition in cancer therapy? | Cancer Treat Rev | 2014 |
| 24857111 | Patient-derived xenograft models in gynecologic malignancies. | Am Soc Clin Oncol Educ Book | 2014 |
| 24619793 | North Central Cancer Treatment Group/Alliance trial N08CA-the use of glutathione for prevention of paclitaxel/carboplatin-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled study. | Cancer | 2014 |
| 24398046 | Tumorgrafts as in vivo surrogates for women with ovarian cancer. | Clin Cancer Res | 2014 |
| 24390424 | Phase 1b study of safety, tolerability and efficacy of R1507, a monoclonal antibody to IGF-1R in combination with multiple standard oncology regimens in patients with advanced solid malignancies. | Cancer Chemother Pharmacol | 2014 |
| 23934194 | Epithelial ovarian cancer experimental models. | Oncogene | 2014 |
| 23470967 | Developing safety criteria for introducing new agents into neoadjuvant trials. | Clin Cancer Res | 2013 |
| 24363999 | Patient-derived xenograft models to improve targeted therapy in epithelial ovarian cancer treatment. | Front Oncol | 2013 |
| 24130056 | Dual HER/VEGF receptor targeting inhibits in vivo ovarian cancer tumor growth. | Mol Cancer Ther | 2013 |
| 23605083 | A phase I trial of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancer. | Breast Cancer Res Treat | 2013 |
| 23796991 | Two birds with one stone: octreotide treatment for acromegaly and breast cancer. | J Clin Oncol | 2013 |
| 21881915 | Phase I study of temsirolimus in combination with EKB-569 in patients with advanced solid tumors. | Invest New Drugs | 2012 |
| 23169510 | Adaptive trials in the neoadjuvant setting: a model to safely tailor care while accelerating drug development. | J Clin Oncol | 2012 |
| 23045324 | Hormone response in ovarian cancer: time to reconsider as a clinical target? | Endocr Relat Cancer | 2012 |